Logo image of ENTX

ENTERA BIO LTD (ENTX) Stock Overview

USA - NASDAQ:ENTX - IL0011429839 - Common Stock

2.5 USD
+0.15 (+6.38%)
Last: 10/20/2025, 12:40:58 PM

ENTX Key Statistics, Chart & Performance

Key Statistics
Market Cap114.15M
Revenue(TTM)166.00K
Net Income(TTM)-10602000
Shares45.66M
Float34.56M
52 Week High2.95
52 Week Low1.5
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.14
PEN/A
Fwd PEN/A
Earnings (Next)11-06 2025-11-06/amc
IPO2018-06-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ENTX short term performance overview.The bars show the price performance of ENTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 30

ENTX long term performance overview.The bars show the price performance of ENTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150 200

The current stock price of ENTX is 2.5 USD. In the past month the price increased by 30.56%. In the past year, price increased by 27.03%.

ENTERA BIO LTD / ENTX Daily stock chart

ENTX Latest News, Press Relases and Analysis

ENTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.8 407.92B
AMGN AMGEN INC 13.81 162.19B
GILD GILEAD SCIENCES INC 15.94 153.08B
VRTX VERTEX PHARMACEUTICALS INC 24.79 107.66B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 64.31B
REGN REGENERON PHARMACEUTICALS 12.7 61.43B
ARGX ARGENX SE - ADR 92.17 52.26B
INSM INSMED INC N/A 35.09B
ONC BEONE MEDICINES LTD-ADR 5.13 34.90B
BNTX BIONTECH SE-ADR N/A 25.84B
NTRA NATERA INC N/A 26.59B
BIIB BIOGEN INC 9.17 21.52B

About ENTX

Company Profile

ENTX logo image Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Company Info

ENTERA BIO LTD

Hadassah / Jerusalem Bio, Park, 5th Floor

JERUSALEM 9112002 IL

CEO: Spiros Jamas

Employees: 19

ENTX Company Website

ENTX Investor Relations

Phone: 97225327151

ENTERA BIO LTD / ENTX FAQ

What is the stock price of ENTERA BIO LTD today?

The current stock price of ENTX is 2.5 USD. The price increased by 6.38% in the last trading session.


What is the ticker symbol for ENTERA BIO LTD stock?

The exchange symbol of ENTERA BIO LTD is ENTX and it is listed on the Nasdaq exchange.


On which exchange is ENTX stock listed?

ENTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ENTERA BIO LTD stock?

7 analysts have analysed ENTX and the average price target is 10.2 USD. This implies a price increase of 308% is expected in the next year compared to the current price of 2.5. Check the ENTERA BIO LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ENTERA BIO LTD worth?

ENTERA BIO LTD (ENTX) has a market capitalization of 114.15M USD. This makes ENTX a Micro Cap stock.


How many employees does ENTERA BIO LTD have?

ENTERA BIO LTD (ENTX) currently has 19 employees.


What are the support and resistance levels for ENTERA BIO LTD (ENTX) stock?

ENTERA BIO LTD (ENTX) has a support level at 2.34 and a resistance level at 2.66. Check the full technical report for a detailed analysis of ENTX support and resistance levels.


Is ENTERA BIO LTD (ENTX) expected to grow?

The Revenue of ENTERA BIO LTD (ENTX) is expected to decline by -69.78% in the next year. Check the estimates tab for more information on the ENTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ENTERA BIO LTD (ENTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ENTERA BIO LTD (ENTX) stock pay dividends?

ENTX does not pay a dividend.


When does ENTERA BIO LTD (ENTX) report earnings?

ENTERA BIO LTD (ENTX) will report earnings on 2025-11-06, after the market close.


What is the Price/Earnings (PE) ratio of ENTERA BIO LTD (ENTX)?

ENTERA BIO LTD (ENTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.14).


What is the Short Interest ratio of ENTERA BIO LTD (ENTX) stock?

The outstanding short interest for ENTERA BIO LTD (ENTX) is 0.14% of its float. Check the ownership tab for more information on the ENTX short interest.


ENTX Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ENTX. When comparing the yearly performance of all stocks, ENTX is one of the better performing stocks in the market, outperforming 83.1% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ENTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ENTX. ENTX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ENTX Financial Highlights

Over the last trailing twelve months ENTX reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS increased by 46.15% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -53.91%
ROE -61.44%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%-100%
EPS 1Y (TTM)46.15%
Revenue 1Y (TTM)N/A

ENTX Forecast & Estimates

7 analysts have analysed ENTX and the average price target is 10.2 USD. This implies a price increase of 308% is expected in the next year compared to the current price of 2.5.

For the next year, analysts expect an EPS growth of -30.56% and a revenue growth -69.78% for ENTX


Analysts
Analysts82.86
Price Target10.2 (308%)
EPS Next Y-30.56%
Revenue Next Year-69.78%

ENTX Ownership

Ownership
Inst Owners22.05%
Ins Owners2.42%
Short Float %0.14%
Short Ratio0.3